STAT5 fulfills essential roles in hematopoietic stem cell (HSC) self-renewal and chronic myeloid leukemia (CML), a prototypical stem cell malignancy. However, the specific contributions of the two related genes STAT5A and STAT5B have not been determined. In this study, we used an RNAi-based strategy to establish participation of these genes to CML disease and persistence following targeted therapy. We showed that STAT5A/STAT5B double knockdown triggers CML cell apoptosis and suppresses both normal and CML HSC long-term clonogenic potential. STAT5A and STAT5B exhibited similar pro-survival activity, but STAT5A attenuation alone was ineffective at impairing growth of normal and CML
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+ cells isolated at diagnosis. In contrast, STAT5A attenuation was sufficient to enhance basal oxidative stress and DNA damage of normal CD34 + and CML cells. Further, it weakened the ability to manage exogenous oxidative stress, increased p53 (TRP53)/CHK-2 (CHEK2) stress pathway activation and enhanced prolyl hydroxylase domain (PHD)-3 (EGLN3) mRNA expression. Only STAT5A and its transactivation domain-deficient mutant STAT5AD749 specifically rescued these activities. STAT5A attenuation was also active at inhibiting growth of CML CD34 + cells from patients with acquired resistance to imatinib. Our findings demonstrate that STAT5A has a selective role in contributing to stress resistance through unconventional mechanisms, offering new opportunities to eradicate the most primitive and TKI-resistant CML cells with an additional potential to eradicate persistent stem cell populations.
Introduction
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell malignancy characterized by the unique t(9:22) chromosome translocation. This generates the BCR-ABL oncogene, a constitutively activated tyrosine kinase which is the primary oncogenic event causing CML (1) . This has made CML a model for targeted therapies by the use of first (Imatinib mesylate, IM) and second generation tyrosine kinase inhibitors (TKI). Currently, TKI administration leads rapidly to complete cytogenetic remission (CCyR) and major molecular response (MMR) in the majority of patients with CML. However, BCR-ABL mRNA remains detectable in the most immature stem/progenitor cells despite long-term TKI therapy, discontinuation of IM in patients with complete molecular remission results in molecular relapse in 60% patients, and clinical resistance to IM also occurs in approximately 15% patients (2, 3) . These observations highlight the needs to approach mechanisms of CML persistence.
Activation of signal transduction and activator of transcription 5 (STAT5) is a signaling hallmark of CML, reported more than a decade ago (4) . STAT5 plays a central role in the maintenance of murine and human HSC from healthy donors and patients with several types of acute leukemia (5). Inhibition with a dominant negative mutant of STAT5 and STAT5
knockdown impair survival of BCR-ABL expressing cell lines and short-term clonogenic potential of primary CML progenitors, respectively (6, 7). In vivo transplantation of BCR-ABL-expressing murine hematopoietic progenitor cells induces an acute so-called "CML-like" leukemia in recipient animals, which almost disappears in STAT5-deficient background.
Moreover, STAT5 overexpression rendered v-ABL + murine BM cells resistant to IM (8).
These observations demonstrated that STAT5 is essential to the induction of CML-like leukemia by exogenous BCR-ABL and provides resistance to IM in murine models. In the present study, in an attempt to approach mechanisms of CML persistence, we tracked human STAT5 activities by differentially knocking down the two STAT5 genes in normal and CML HSC/progenitor cells, using a RNA interference strategy.
Material and Methods (543)

Cell lines and primary samples
Umbilical cord blood (CB) or adult peripheral blood (PB) samples from healthy donors and CML patients were collected after informed consent, in accordance with the declaration of for one or five weeks before cell plating for colony assays using standard procedures. IM (1.5 µM) was added to the medium of IM-resistant cells. The resulting colony forming cells (CFC) were scored after 14 days of incubation. CML cell lines (MEG01, LAMA84, and K562) were purchased from cell depository banks. IM-resistant LAMA84 or MEG01 cells were generated using escalating concentrations of IM (from 0.05 to 1 µM) over four months. Resistant cells were maintained in IM (1µM)-supplemented medium.
Lentiviral constructs, transductions
The shC, shS5A, shS5B and shS5A/B sequences (see Supplementary Information) were inserted downstream of the H1 promoter into pTRIPΔU3-EF1α which encodes green fluorescent protein (GFP) or human CD4 as reporters. Murine STAT5A or STAT5B cDNA were introduced into pTRIPΔU3-EF1α ahead of IRESEMCV-GFP sequence. VSV-Gpseudotyped lentiviral particles were generated as described (11). 85-98% and 70-90% transduction with CML cell lines and CD34 + cells, respectively, were obtained as measured by GFP expression. Cells were FACS-sorted when required. All subsequent assays were performed at day 7 post transduction. For rescue assays, cells were transduced with shRNA/CD4 encoding vectors and maintained in culture for 4 days before adding the cDNA/GFP rescue vectors. Assays were performed at day 3-5 post 2 nd transduction.
Cytofluorometric analysis
Cell viability and cell cycle were assessed after staining with AnnexinV/7AAD, or propidium 
Western blot analysis
Cell extracts were analyzed by standard procedures using commercially available primary and peroxidase-labeled secondary antibodies (see Supplementary Information) . Protein signals were detected by chemiluminescence (GE Healthcare) and quantified using a Fuji-LAS4000 image analyzer.
Immunofluorescence
Immunofluorescence assays were performed by standard procedures using anti-γH2Ax (Cell Signaling Technology) or anti-RAD51 (Pharmingen) antibody and Alexa 546-conjugated anti-rabbit Ig.
Q-PCR
Total RNA was extracted using RNeasy mini kit (Qiagen); Quantitative PCR was performed using SYBR green kit on a Lightcycler (Roche). Data were normalized to HPRT mRNA expression.
Statistical analysis
Data were expressed as mean ± SEM. Student's t-test was used for statistical analysis. 
Results and discussion
STAT5 is required for long-term maintenance of normal and CML HSC
We identified three small hairpin RNAs (shRNAs) that differentially knockdown human STAT5A and STAT5B factors, thereafter named shS5A, shS5B and shS5A/B. These were stably introduced into three CML cell lines (K562, LAMA84, and MEG01) using lentiviral vectors that co-encode the GFP dye, and immunoblot analyses of the transduced cells were performed ( Murine STAT5B which is insensitive to shS5B reversed STAT5B expression to endogenous levels in shS5B + cells (Fig. 1D, inset) ; it simultaneously rescued shS5B + cell survival, as assessed by the maintenance of mSTAT5 + shS5B + doubly-transduced cells in culture (Fig. 1D ).
These observations assessed that shS5B activities were not "off-target" effects. Murine STAT5A was then introduced in place of STAT5B and similarly rescued shS5B + cell growth (Fig. 1D) . These results indicated that the two STAT5s commonly sustain CML cell survival.
Because shS5A -which inhibited STAT5A only-was inactive at altering CML cell growth, as opposed to shS5B which inhibited both STAT5B and STAT5A, the data further suggested that CML cell growth is sensitive to STAT5 gene dosage.
We next examined STAT5 activities in the context of primary CML stem/progenitor cells. (Fig. 3C) . Activation of this p53/CHK2 stress response pathway was not detectable by this approach in normally growing shS5A + cells.
Overall, these data indicated that shS5A enhances cell oxidative/replicative/genomic stress, as compared to controls, and Nox activity contributes to this action. 
that associates with the central Nox regulator Rac1 (13, 14) . STAT5A may thus participate to a negative regulatory loop that limits cellular ROS. Among ROS cellular sensors is the oxygen-dependent prolyl hydroxylase domain (PHD) family. All three sh5A + CML cell lines showed enhanced PHD3 expression as compared to controls. This activity was reversed upon shS5A-resistant murine STAT5A and transcription-deficient mutant STAT5AΔ749, but not STAT5B, expression; it was not duplicated by shS5B that weakly inhibits STAT5A (Fig. 3D) .
Collectively, our results indicated that STAT5A exhibits the restricted property to limit CML and normal stem/progenitor cell stress, independently of its canonical transcriptional activity.
In line with these data, STAT5 down-regulates ROS production in pre-B leukemic cell lines, As compared to untreated cells, shS5A reduced cell viability of IM-treated cells (Fig. 4B) . activity, and over-expressed or over-active STAT5 (Supplementary Fig. S4 ). However, shS5A greatly affected growth of IM-resistant but not parental CML cells (Fig. 4C ).
Secondary IM-resistant patients were further selected that i) show no BCR-ABL overexpression or over-activity (no BCR-ABL mutations); ii) exhibit IM-resistant CD34 + cell clonogenic properties. These IM-resistant CD34 + cells did not express enhanced STAT5A/STAT5B mRNA levels and STA5A/STAT5B protein ratios (Fig. 4A and Supplementary Fig. S5 ). They, however, showed decreased clonogenic potential upon STAT5A knockdown (Fig. 4D) , as opposed to CML CD34 + cells at diagnosis (Fig. 2A) . 
